The Food and Drug Administration is weighing whether to follow British regulators in resuming a coronavirus vaccine trial that was halted when a participant suffered spinal cord damage, even as the National Institutes of Health has launched an investigation of the case.
NIH ‘very concerned’ about serious side effect in AstraZeneca coronavirus vaccine trial
December 6, 2021By
NIH ‘very concerned’ about serious side effect in AstraZeneca coronavirus vaccine trial
October 9, 2020By
The Food and Drug Administration is weighing whether to follow British regulators in resuming a coronavirus vaccine trial that was halted when a participant suffered spinal cord damage, even as the National Institutes of Health has launched an investigation of the case.
AstraZeneca, Merck eye $1 billion boost from cancer drug success
June 27, 2018By
LONDON (Reuters) – AstraZeneca’s oncology business received a boost on Wednesday as results of a clinical trial showed its drug Lynparza helped women with ovarian cancer live longer without their disease worsening when given as a first-line treatment.
AstraZeneca sells rights for Seroquel to Luye Pharma for $538 million
May 8, 2018By
LONDON (Reuters) – British pharma company AstraZeneca said it had sold the rights for Seroquel, a treatment for schizophrenia and bipolar disease, to Luye Pharma Group for $ 538 million, as part of a strategy to focus on other therapy areas.
AstraZeneca in broad drug deal with Bicycle worth up to $1 bln
December 1, 2016By
LONDON (Reuters) – AstraZeneca has signed a wide-ranging deal with private biotech firm Bicycle Therapeutics to develop a novel class of small molecule medicines for treating respiratory, cardiovascular and metabolic diseases.
AstraZeneca sells drug for $70 million as divestment drive continues
March 1, 2016By
LONDON (Reuters) – AstraZeneca has sold rights to a non-core drug to a unit of Kyowa Hakko Kirin for an upfront payment of $ 70 million, a day after getting $ 500 million for two ageing heart medicines.
